Intrexon | XON - Operating Profit


Intrexon reported $-60.84M in Operating Profit for its fiscal quarter ending in June of 2024.





Operating Profit Change Date
Agenus USD 15.05M 656K Mar/2026
Alaunos Therapeutics USD -952K 60K Jun/2026
Amgen USD 4.68B 65M Sep/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -170.09M 28.83M Jun/2026
AstraZeneca USD 4.66B 1.5B Sep/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
GlaxoSmithKline GBP 2.86B 251M Sep/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Incyte USD -707.47M 1.41B Sep/2026
Intrexon USD -60.84M 26.62M Jun/2024
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
Ligand Pharmaceuticals USD 54.53M 2.1M Sep/2026
MacroGenics USD -13.85M 19.59M Jun/2026
MannKind USD -59.44M 8.79M Sep/2026
Merck USD 7.33B 6.49B Sep/2026
Novartis USD 5.14B 392M Sep/2026
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Roche Holding CHF 11.46B 1.91B Jun/2026
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Thermo Fisher Scientific USD 2.46B 277M Sep/2026
Veracyte USD 18.02M 5.94M Sep/2026
Xencor USD -36.6M 41.26M Jun/2026